US Patent Issued to Ventus Therapeutics U.S. on Oct. 14 for "Pyridazine compounds for inhibiting NLRP3" (Canadian Inventor)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,441,728, issued on Oct. 14, was assigned to Ventus Therapeutics U.S. Inc. (Waltham, Mass.).

"Pyridazine compounds for inhibiting NLRP3" was invented by Stephane Dorich (Pointe-Claire, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein and having the Formula (I):"

The patent was filed on Oct. 4, 2023, under Application No. 18/480,925.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&...